Quick Answer
Kura Oncology, Inc. reported Stockholders Equity of $174.13 million for fiscal year 2025.
Kura Oncology, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $174.13M | -57.9% |
| 2024 | $413.64M | +4.1% |
| 2023 | $397.27M | -5.5% |
| 2022 | $420.28M | -17.0% |
| 2021 | $506.61M | -17.1% |
| 2020 | $610.90M | +179.2% |
| 2019 | $218.78M | +35.9% |
| 2018 | $160.99M | +101.6% |
| 2017 | $79.86M | +40.4% |
| 2016 | $56.88M | -30.7% |
| 2015 | $82.10M | +2491.6% |
| 2014 | -$3.43M | — |
| 2014 | $0.00 | +100.0% |
| 2013 | -$124.0K | -30.0% |
| 2012 | -$95.3K | -40.2% |
| 2011 | -$68.0K | -66.0% |
| 2010 | -$41.0K | -120.4% |
| 2009 | -$18.6K | -1428.3% |
| 2008 | $1.4K | -96.0% |
| 2007 | $35.0K | — |
| 2007 | $0.00 | — |
| 2007 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $242.54M | -42.8% | -20.6% |
| June 30, 2025 | $305.49M | -34.5% | -16.2% |
| March 31, 2025 | $364.41M | -27.9% | -11.9% |
| December 31, 2024 | $413.64M | +4.1% | -2.4% |
| September 30, 2024 | $423.77M | -1.4% | -9.1% |
| June 30, 2024 | $466.07M | +1.4% | -7.7% |
| March 31, 2024 | $505.08M | +27.8% | +27.1% |
| December 31, 2023 | $397.27M | -5.5% | -7.6% |
- Kura Oncology, Inc. showed a decrease of -57.9% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Kura Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: